Gritstone Oncology Inc.

12.79+1.21+10.45%Vol 1.27M1Y Perf 303.14%
Sep 15th, 2021 16:00 DELAYED
BID12.59 ASK13.00
Open11.58 Previous Close11.58
Pre-Market- After-Market-
 - -%  - -
Target Price
24.00 
Analyst Rating
Strong Buy 1.25
Potential %
87.65 
Finscreener Ranking
★★★★     53.83
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     48.83
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★     47.28
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
31.38 
Earnings Rating
Strong Buy
Market Cap632.44M 
Earnings Date
4th Nov 2021
Alpha0.07 Standard Deviation0.65
Beta0.16 

Today's Price Range

11.4012.96

52W Range

2.5435.20

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
9.22%
1 Month
59.88%
3 Months
31.86%
6 Months
-10.18%
1 Year
303.14%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GRTS12.791.210010.45
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.53-0.3337.74
Q01 2021-0.460.10121.74
Q04 2020-0.69-0.690.00
Q03 2020-0.68-0.69-1.47
Q02 2020-0.77-0.6910.39
Q01 2020-0.83-0.7114.46
Q04 2019-0.76-0.77-1.32
Q03 2019-0.68-0.77-13.24
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.4425.42Positive
12/2021 QR-0.5115.00Positive
12/2021 FY-1.0126.81Positive
12/2022 FY-1.2231.84Positive
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.44
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.27M
Shares Outstanding49.45M
Shares Float40.26M
Trades Count10.01K
Dollar Volume6.36M
Avg. Volume1.61M
Avg. Weekly Volume997.53K
Avg. Monthly Volume894.07K
Avg. Quarterly Volume725.40K

Gritstone Oncology Inc. (NASDAQ: GRTS) stock closed at 12.79 per share at the end of the most recent trading day (a 10.45% change compared to the prior day closing price) with a volume of 1.29M shares and market capitalization of 632.44M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 177 people. Gritstone Oncology Inc. CEO is Andrew R. Allen.

The one-year performance of Gritstone Oncology Inc. stock is 303.14%, while year-to-date (YTD) performance is 224.62%. GRTS stock has a five-year performance of %. Its 52-week range is between 2.54 and 35.2, which gives GRTS stock a 52-week price range ratio of 31.38%

Gritstone Oncology Inc. currently has a PE ratio of -7.60, a price-to-book (PB) ratio of 3.37, a price-to-sale (PS) ratio of 13.23, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.27%, a ROC of -43.57% and a ROE of -50.24%. The company’s profit margin is -93.01%, its EBITDA margin is -142.80%, and its revenue ttm is $44.82 Million , which makes it $0.91 revenue per share.

Of the last four earnings reports from Gritstone Oncology Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.44 for the next earnings report. Gritstone Oncology Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Gritstone Oncology Inc. is Strong Buy (1.25), with a target price of $24, which is +87.65% compared to the current price. The earnings rating for Gritstone Oncology Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Gritstone Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Gritstone Oncology Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 25.13, ATR14 : 0.86, CCI20 : 108.25, Chaikin Money Flow : 0.11, MACD : 1.12, Money Flow Index : 67.94, ROC : 43.06, RSI : 73.15, STOCH (14,3) : 96.10, STOCH RSI : 0.64, UO : 56.49, Williams %R : -3.90), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Gritstone Oncology Inc. in the last 12-months were: Erin Jones (Option Excercise at a value of $690), Erin Jones (Sold 2 000 shares of value $22 748 ), Raphael Rousseau (Option Excercise at a value of $25 001), Raphael Rousseau (Sold 32 900 shares of value $627 381 ), Roman Yelensky (Option Excercise at a value of $38 500), Roman Yelensky (Sold 10 000 shares of value $221 029 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.25
Strong Buy
1.25

Gritstone Oncology Inc.

Gritstone Oncology Inc is a United States based immune-oncology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors including GRANITE-001 and SLATE-001.

CEO: Andrew R. Allen

Telephone: +1 510 871-6100

Address: 5959 Horton Street, Emeryville 94608, CA, US

Number of employees: 177

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

58%42%

Bearish Bullish

65%35%

News

Stocktwits